期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 16, 期 9, 页码 917-933出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026615666150825142134
关键词
Crystal structure; Cyclic nucleotide signalling pathway; Family-selective inhibitor; Medicinal chemistry; Phosphodiesterases; Structure-based drug design
资金
- CAS-NovoNordisk Great Wall Professorship
- National Natural Science Foundation of China [21172233, 81422047]
Phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP, thereby regulating the cyclic nucleotide signalling pathways and biological responses. PDEs inhibitors can be used clinically for treatment of several diseases including central nervous system disorders, erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, and inflammatory diseases such as chronic obstructive pulmonary disease. However, the unfavourable risk-benefit ratio and side-effect profiles of non-selective PDEs inhibitors have impeded their therapeutic success and therefore spurred the pharmaceutical industry to develop family-selective PDE inhibitors. Given the recent remarkable advances in structure-based drug design, this review will summarize developments and achievements in structure-based search, design and optimization of PDEs inhibitors, and highlight the challenges that need to be addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据